Diabetes is one of the most studied diseases in medicine, yet it remains one of the most misunderstood — partly because "diabetes" isn't really one disease at all. It's a family of related conditions that share a single feature — elevated blood glucose — but arise from very different underlying mechanisms, progress differently, and increasingly, don't fit neatly into the categories most people grew up hearing about. Here's a complete look at what diabetes actually is, how it's classified, what causes it, how it's diagnosed and managed worldwide, and where the science is still evolving.

What Diabetes Actually Is

Diabetes mellitus is a group of metabolic disorders in which the body either doesn't produce enough insulin, doesn't use insulin effectively, or both. Insulin is the hormone responsible for allowing glucose to move from the bloodstream into cells, where it's used for energy. When that system breaks down, glucose builds up in the blood, and over years, that chronic excess damages blood vessels and organs throughout the body — which is why diabetes is as much a vascular disease as it is a metabolic one.

The Global Scale of Diabetes

According to the International Diabetes Federation's 11th edition Diabetes Atlas (2025), an estimated 589 million adults aged 20–79 are living with diabetes worldwide — 11.1% of that age group. That number is projected to climb to roughly 853 million by 2050. Perhaps the most sobering figure: an estimated 252 million people with diabetes don't yet know they have it.

China and India carry the two largest national disease burdens globally, with India alone accounting for approximately 89 million cases. South and East Asia have emerged as the epicenter of the global diabetes epidemic — not simply due to population size, but because diabetes in this region tends to appear earlier in life, in leaner individuals, and progress differently than the classical Western pattern most diagnostic frameworks were originally built around.

The Types of Diabetes, Explained

Type 1 Diabetes

An autoimmune condition in which the immune system mistakenly destroys insulin-producing beta cells in the pancreas. It typically presents in childhood or young adulthood, though the ADA's 2025 guidance is explicit that Type 1 diabetes can occur at any age — challenging older assumptions that it's exclusively a childhood disease. People with Type 1 diabetes require insulin for survival, since their bodies produce little to none of it. The presence of multiple islet autoantibodies is a strong predictor of eventual clinical Type 1 diabetes.

Type 2 Diabetes

The most common form globally, accounting for roughly 90% of all diabetes cases. It develops when the body becomes resistant to insulin's effects and, over time, the pancreas can no longer produce enough insulin to compensate. It's strongly associated with excess body weight, physical inactivity, and genetic predisposition, though — as discussed below — the "typical" Type 2 profile looks meaningfully different across populations.

Gestational Diabetes

Diabetes first diagnosed during pregnancy, resulting from hormonal changes that increase insulin resistance. It usually resolves after delivery but significantly raises a woman's lifetime risk of developing Type 2 diabetes later on, and requires careful management to reduce risks to both mother and baby.

Monogenic Diabetes (MODY and Neonatal Diabetes)

A form of diabetes caused directly by a mutation in a single gene, rather than the complex, multi-gene-and-lifestyle interplay behind Type 1 and Type 2. It includes Maturity-Onset Diabetes of the Young (MODY) and neonatal diabetes (onset before 6 months of age). Over 43 genes have now been linked to monogenic diabetes, and it's estimated to represent 1–6% of all diabetes cases — a small percentage that, at global case numbers, still adds up to millions of people. It's also widely documented as underdiagnosed and frequently misclassified as Type 1 or Type 2, because its clinical presentation overlaps with both. This distinction matters clinically: some monogenic subtypes (like GCK-related diabetes) need no medication at all, while others (like HNF1A- or HNF4A-related diabetes) often respond far better to sulfonylurea tablets than to insulin — even in patients previously started on insulin under the wrong label.

Type 5 Diabetes — A Newly Recognized Category (2025)

In January 2025, an international consensus — subsequently endorsed by the IDF World Diabetes Congress — formally recognized a phenotype first described in 1955 but long neglected: Type 5 diabetes. It occurs in lean individuals with a lifelong history of undernutrition, and is marked by severely impaired insulin secretion alongside preserved insulin sensitivity — essentially the inverse metabolic signature of typical Type 2 diabetes. It's estimated to affect 20–25 million people worldwide, concentrated in low- and middle-income countries, and existing Type 1/Type 2 treatment protocols are considered inadequate for it. This reclassification is a useful reminder that diabetes categories are not fixed textbook fact — they continue to evolve as science catches up with the real diversity of patients.

What Causes Diabetes: Risk Factors by Type

• Type 1: Autoimmune destruction of beta cells, with genetic susceptibility (certain HLA gene variants) and as-yet-incompletely-understood environmental triggers.
• Type 2: A combination of genetic predisposition, excess body weight (particularly visceral fat), physical inactivity, aging, and — increasingly recognized — ethnicity-specific differences in how body fat and insulin resistance interact.
• Gestational: Pregnancy-related hormonal changes, with higher risk in women who are older, overweight, or have a family history of diabetes.
• Monogenic: A single inherited gene mutation, typically following autosomal dominant inheritance (meaning each child of an affected parent has roughly a 50% chance of inheriting it).
• Type 5: Chronic undernutrition during critical developmental periods, thought to impair pancreatic development itself.

ADA risk-assessment guidance for Type 2 diabetes and prediabetes screening in asymptomatic adults highlights a cluster of risk factors: overweight or obesity, a history of cardiovascular disease, hypertension (≥130/80 mmHg), high triglycerides, low HDL cholesterol, polycystic ovary syndrome, physical inactivity, and a family history of diabetes.

Recognizing the Symptoms

Common symptoms across diabetes types include excessive thirst (polydipsia), frequent urination (polyuria), unexplained hunger (polyphagia), unexplained weight loss, blurry vision, and extreme fatigue. Type 1 diabetes often presents more suddenly and dramatically, sometimes with diabetic ketoacidosis as the first sign. Type 2 diabetes frequently develops silently over years, which is a major reason such a large share of cases worldwide remain undiagnosed until complications appear.

How Diabetes Is Diagnosed

International diagnostic criteria, as codified in the ADA's Standards of Care (updated annually, most recently for 2026), rely on any of the following:

Prediabetes is defined by values that fall short of these thresholds but above normal — an HbA1c of 5.7–6.4%, for instance — and significantly raises future risk of both diabetes and cardiovascular disease. Certain conditions (anemia, hemoglobin variants, pregnancy, kidney dialysis, HIV treatment) can distort A1c results, in which case direct plasma glucose testing is used instead.

The Complications: Why Long-Term Control Matters

Diabetes complications are broadly split into two categories:

Microvascular complications (damage to small blood vessels):

• Retinopathy — damage to blood vessels in the retina, a leading cause of preventable blindness in adults
• Nephropathy — progressive kidney damage that can lead to chronic kidney disease and kidney failure
• Neuropathy — nerve damage, often first noticed as numbness or tingling in the feet, which also raises the risk of foot ulcers and, in severe cases, amputation

Macrovascular complications (damage to larger blood vessels):

• Cardiovascular disease, including heart attack and heart failure
• Cerebrovascular disease, including stroke
• Peripheral arterial disease

Diabetes-related cardiovascular disease remains the leading cause of death among people with diabetes globally. Encouragingly, large randomized trials have consistently shown that intensive, sustained glycemic management can prevent or meaningfully delay the onset and progression of retinopathy specifically, and similar principles apply across other complications — which is the central rationale behind aggressive early treatment.

How Diabetes Is Treated

Management approaches differ meaningfully by type, but the global treatment landscape includes:

• Lifestyle intervention — nutrition changes, physical activity, and weight management remain foundational across nearly all forms of Type 2 diabetes and prediabetes.
• Metformin — typically the first-line oral medication for Type 2 diabetes worldwide, improving insulin sensitivity.
• SGLT2 inhibitors — a newer drug class that lowers blood glucose by promoting glucose excretion through urine, with demonstrated cardiovascular and kidney-protective benefits in Type 2 diabetes.
• GLP-1 receptor agonists (GLP-1 RAs) — one of the most significant recent developments in diabetes treatment, this class (including semaglutide, liraglutide, and dulaglutide) improves glycemic control and has shown notable cardiovascular benefits, including reduced ischemic stroke risk in trial meta-analyses. Retinopathy status is specifically monitored when starting these medications, since rapid A1c reduction has been associated with initial, transient worsening in some patients with existing retinopathy.
• Insulin therapy — essential for all Type 1 diabetes, and used in Type 2 diabetes when other therapies aren't sufficient to reach glycemic targets.
• Sulfonylureas — often highly effective for specific monogenic diabetes subtypes (HNF1A, HNF4A), sometimes allowing patients to come off insulin entirely once correctly diagnosed.

Ongoing care also includes structured screening: eye exams for retinopathy, kidney function monitoring for nephropathy, foot exams for at-risk patients (especially those with sensory loss, prior ulcers, or long diabetes duration), and cardiovascular risk assessment — all recommended as routine, recurring parts of diabetes management under current international standards of care.

Prevention: What the Evidence Actually Supports

For Type 2 diabetes, large randomized trials (e.g., the Diabetes Prevention Program) have demonstrated that lifestyle modification—achieving and maintaining 5–7% weight loss, increasing physical activity to at least 150 minutes per week—can reduce the incidence of diabetes by 58% in high-risk individuals. Metformin also reduced risk by 31% in the same trial, though lifestyle was more effective. For Type 1 diabetes, no preventive strategy is currently proven, though research into immunotherapy and beta-cell preservation is ongoing. Gestational diabetes prevention focuses on early screening and lifestyle counseling in at-risk pregnancies. Monogenic diabetes prevention is not applicable, as it is genetic; however, early genetic testing can prevent misdiagnosis and optimize treatment. Type 5 diabetes prevention centers on improving maternal and childhood nutrition in low-resource settings.